Search

Allogeneic processed thymus tissue

Allogeneic processed thymus tissue is used for immune reconstitution in immune disorders where the patients are severely immunocompromised due to the absence of a functional thymus, such as congenital … [A239814] On October 8, 2021, FDA approved allogeneic processed thymus tissue-agdc, under the market name RETHYMIC, as a one-time regenerative tissue-based therapy for immune reconstitution in pediatric

Besilesomab

Besilesomab is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis … Utilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the

Ferric chloride

Fludrocortisone

Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.

Umbralisib

While it initially offered a promising therapy for patients experiencing relapsing or refractory disease,[A229363] umbralisib was withdrawn from the market due to safety concerns as the drug was associated … Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with [rituximab] (an anti-CD20 drug), either alone or in combination with chemotherapy.

Naxitamab

[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely … Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.

Anisotropine methylbromide

action on the bile ducts and gallbladder. … Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents.

Penicillamine

The pharmaceutical form is D-penicillamine, as L-penicillamine is toxic (it inhibits the action of pyridoxine). … It is an α-amino acid metabolite of penicillin, although it has no antibiotic properties.

BF-1

BF-1 is an investigational 5-HT2B receptor antagonist developed for the prophylaxis of Migraines.

Desflurane

It was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled anesthetic.[A226883,A226888] Desflurane was granted FDA approval on 18 September 1992.[L30285]